CLSN - CLSN STOCK NEWS

Celsion Corporation (NASDAQ: CLSN) announced the adjournment of its 2021 Annual Meeting of Stockholders due to a lack of quorum, with only 49% of shares voted. The meeting will reconvene at 4:00 p.m. on the same day, June 4, 2021. Stockholders with unvoted proxies are strongly encouraged to cast their votes. Celsion focuses on DNA-based immunotherapy and next-generation vaccines, with a pipeline including GEN-1 for ovarian cancer and ThermoDox for various cancer indications.

Celsion Corporation (NASDAQ: CLSN) has announced a virtual Annual Meeting of Stockholders on June 4, 2021, at 10:00 a.m. Eastern Time. Shareholders holding common stock as of April 5, 2021, are eligible to vote. The company emphasizes the importance of shareholder votes to meet quorum requirements. One key proposal, supported by ISS and Glass Lewis, seeks to increase the authorized shares of common stock from 112.5 million to 172.5 million to facilitate future growth and opportunities. Stockholders are urged to cast their votes to ensure representation at the meeting.

Celsion Corporation (NASDAQ: CLSN) announced its virtual Annual Meeting of Stockholders on June 4, 2021, urging shareholders to vote to ensure a quorum is met. Stockholders who owned shares as of April 5, 2021, are eligible to vote. The company is recommending a vote in favor of Proposal #3, which aims to increase authorized shares from 112.5 million to 172.5 million to support future growth and business opportunities. Shareholders are encouraged to vote online or return proxy cards to ensure their shares are counted.

Celsion Corporation (NASDAQ: CLSN) reported financial results for Q1 2021, showing a net loss of $5.7 million ($0.09 per share), compared to a net loss of $5.1 million ($0.20 per share) in the same quarter last year. The company raised over $58 million from various financing methods, extending its cash runway through 2024. Celsion’s GEN-1 immunotherapy for ovarian cancer has shown promising interim results, with an 81% R0 resection rate in treated patients. Additionally, the company received FDA Fast Track designation for GEN-1 and filed a provisional patent for a next-generation DNA vaccine against infectious agents.

Celsion Corporation (NASDAQ: CLSN) announced a significant financial boost by receiving $1.85 million from the sale of about $2.0 million of unused New Jersey net operating losses (NOLs). This funding strengthens its balance sheet alongside more than $58 million from previous equity offerings, extending its cash runway past 2024. An additional $5.0 million in NOLs is planned for future sale, enhancing cash flow to support ongoing clinical programs, including the OVATION 2 Study targeting advanced ovarian cancer.

Celsion Corporation (NASDAQ: CLSN) announced a conference call scheduled for May 14, 2021, at 10:00 a.m. EDT to discuss its Q1 2021 financial results and updates on its product development programs, including GEN-1, a DNA-based immunotherapy for advanced ovarian cancer currently in Phase II, and PLACCINE, a non-viral vaccine delivery technology in preclinical studies. Celsion focuses on innovative cancer treatments and nucleic acid vaccines.

Celsion Corporation (NASDAQ: CLSN) recently participated in Alliance Global Partners' Virtual Series on April 21, 2021. The management team, including Chairman and CEO Michael H. Tardugno and EVP and CSO Kursheed Anwar, discussed the company’s lead product, GEN-1, a DNA-based immunotherapy for ovarian cancer in Phase II studies, along with its PLACCINE vaccine development platform. As a clinical-stage biotech firm, Celsion focuses on innovative cancer therapies.

Celsion Corporation (NASDAQ: CLSN) announced the closing of its registered direct offering of 11,538,462 shares at $1.30 per share, raising net proceeds of $13.9 million after fees. A.G.P./Alliance Global Partners led the offering, with JonesTrading and Brookline Capital acting as co-placement agents. The funds will be used for general corporate purposes, including research and development and working capital. The offering utilized an effective registration statement filed with the SEC. No solicitation or sale activity occurred in jurisdictions where it would be illegal.

Celsion Corporation (NASDAQ: CLSN) announced positive interim results from its Phase I/II OVATION 2 Study of GEN-1 for advanced ovarian cancer. The study showed an encouraging 82% R0 resection rate in patients receiving GEN-1 combined with neoadjuvant chemotherapy (NACT), compared to 58% in the control group. The study aims to improve progression-free survival. Celsion has enrolled approximately 40% of the planned 110 patients and received Fast Track designation from the FDA to expedite development. The results suggest GEN-1 could become a valuable treatment option for patients.